The use of TNF-α antagonists in RA reduces the risk of CHD events, such as MI, cardiac death, and unstable angina, and these risks are further reduced with long-term use [14], but another study shows that compared with receiving conventional modified antirheumatic drugs, the AMI rate is not reduced in RA treated with TNF-α antagonists, and reduction in this risk presupposes a response to TNF-α antagonists [17]. The gene discussed is TNF; the disease is angina unstable.